Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Chris Buyse | M | 59 |
Fund+
 Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | 16 years |
| Christiaan de Wilde | M | - |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 18 years |
| Philippe Monteyne | M | - |
Fund+
Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | 9 years |
| Sally Jackson | F | - | 23 years | |
| Timothy Woodthorpe | M | - | 24 years | |
| Graham Rivers | M | - | 26 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas Lienard | M | 48 | 5 years | |
| Wim Goemaere | M | - | 5 years | |
| Claudia D'Augusta | M | 54 | - | |
| Frank Morich | M | 69 |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 2 years |
| Thierry François | M | - | - | |
| Marc Nolet de Brauwere | M | - | 2 years | |
| Baron Jean Stéphenne | M | 73 | - | |
| Jacques Reymann | M | - | 11 years | |
| Valérie Gangji | M | - | - | |
| Julian Heslop | M | 70 | 13 years | |
| Jean-Luc Vandebroek | M | 53 | - | |
| Roland Baron | M | - | 4 years | |
| Michèle Barzach | M | - | 7 years | |
| John David Coombe | M | 79 | 5 years | |
| Ian Maurice Gray Prosser | M | 81 | 9 years | |
| Damian Marron | M | 62 | - | |
| Steven Swinson | M | - | 1 years | |
| Murray Stewart | M | 63 | 17 years | |
| Peter Traber | M | 69 | 3 years | |
| Jean-Pierre Garnier | M | 75 | 8 years | |
| Dirk Dembski | M | - | 2 years | |
| Marc van Dijk | M | 61 |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 3 years |
| Jan Van den Bossche | M | - |
Fund+
Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | 7 years |
| Robert J. DiVasto | M | 68 | 2 years | |
| Vera Goossens | M | - |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 5 years |
| Filip Goossens | M | - |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 6 years |
| Miguel Forte | M | 63 | - | |
| Song Gao | M | 52 | 22 years | |
| Denis Brodsky | M | 53 | 5 years | |
| Melissa Beelen | F | - | 12 years | |
| David Rowe | M | 57 | 20 years | |
| Edgar Cale | M | 60 | 21 years | |
| Kimberly Park | F | 60 | 12 years | |
| Marie Paule Richard | M | 72 | 1 years | |
| Lieve Nuytinck | M | - |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | - |
| David Wheadon | M | 66 | 5 years | |
| Lawson Macartney | M | 66 | 12 years | |
| Robin M. Young | M | 57 | 7 years | |
| Michel Baijot | M | - |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 5 years |
| Sjoerd Wadman | M | - | 12 years | |
| Michael Owen | M | 73 | 9 years | |
| Roger Connor | M | - | 24 years | |
| Thierry Loriot | M | - | - | |
| John Lepore | M | - | 15 years | |
| Steven Gelone | M | 56 | 2 years | |
| Jon Ellis | M | 57 | 21 years | |
| Daniel G. Marquess | M | 55 | 4 years | |
| Dean Hakanson | M | 72 | 7 years | |
| Steve Damment | M | - | 17 years | |
| Brian Blakey | M | 61 | 6 years | |
| Vivid Sehgal | M | 56 | 6 years | |
| Anne-Francoise Nesmes | F | 53 | 16 years | |
| Margaret Dalesandro | M | 77 | 2 years | |
| Scott Fields | M | 69 | 5 years | |
| Peter Goodfellow | M | 72 | 8 years | |
| Lucy Shapiro | M | 83 | 5 years | |
| Martin Rosenberg | M | 78 | 5 years | |
| Tamar Howson | F | 75 | 9 years | |
| Werner Cautreels | M | 71 |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 7 years |
| Ronaldo Hermann Schmitz | M | 85 | 9 years | |
| Michael D. Rogers | M | 68 | 6 years | |
| Eric Carter | M | 72 | - | |
| J. Michael Hamilton | M | 75 | 5 years | |
| Wim Ottevaere | M | 68 |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 14 years |
| Christopher Chipman | M | 50 | 2 years | |
| Ursula B. Bartels | F | 66 | 11 years | |
| James R. Beery | M | 83 | 1 years | |
| Robert Ruffolo | M | 74 | 16 years | |
| Tim Tyson | M | 71 | 6 years | |
| John Apeler Keller | M | 60 | - | |
| Dean Mitchell | M | 68 | 15 years | |
| Roger L. Hawley | M | 71 | 14 years | |
| Ian Gilham | M | 64 | - | |
| Argeris Karabelas | M | 71 | 6 years | |
| Edward Littler | M | - | - | |
| Jan van den Bossche | M | 45 |
Fund+
Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | 7 years |
| Anthony S. Murabito | M | - | 19 years | |
| Eddie J. Gray | M | 64 | 12 years | |
| Joseph Schachle | M | 59 | 3 years | |
| Franco di Muzio | M | - | 8 years | |
| Jean-Jacques Verdickt | M | 79 | - | |
| Robert G. Pietrusko | M | 76 | 1 years | |
| Christopher J. Morl | M | 65 | 3 years | |
| Douglas B. Snyder | M | 60 | 6 years | |
| Gary Patou | M | 65 | 5 years | |
| Peter Strong | M | - | 3 years | |
| David Lawrence | M | 61 | 13 years | |
| Rupert Bondy | M | 62 | - | |
| Ford Calhoun | M | - | - | |
| Adrian Rawcliffe | M | 52 | 17 years | |
| Lisa Porter | M | 60 | 5 years | |
| Michael V. Milburn | M | - | 10 years | |
| Elaine Jones | M | 69 | - | |
| Wissam Al-Adani | M | 50 | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 72 | 72.00% |
| Belgium | 28 | 28.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paul Magrez
- Personal Network
